{"id":1635,"date":"2020-09-23T18:00:25","date_gmt":"2020-09-23T18:00:25","guid":{"rendered":"https:\/\/aivfisabio.com\/?page_id=1635"},"modified":"2025-11-19T12:44:37","modified_gmt":"2025-11-19T12:44:37","slug":"ensayos-clinicos","status":"publish","type":"page","link":"https:\/\/aivfisabio.com\/eng\/ensayos-clinicos\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"1635\" class=\"elementor elementor-1635\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-bd00736 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"bd00736\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-0e818ec\" data-id=\"0e818ec\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8092f1a elementor-widget elementor-widget-heading\" data-id=\"8092f1a\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Clinical Trials<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7e60814 elementor-widget elementor-widget-text-editor\" data-id=\"7e60814\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>Los <a href=\"https:\/\/www.youtube.com\/watch?v=yKous-w8y3s\" target=\"_blank\" rel=\"noopener\">Clinical trials<\/a> in vaccines are studies that are carried out to determine whether a new treatment or vaccine works and is safe.\u00a0<\/p><p><span style=\"font-family: var( --e-global-typography-text-font-family ), Sans-serif;\">Below, find a list of our studies: in the recruitment phase, active and past.\u00a0<\/span><\/p><p>If you can't find one that is of interest to you, sign up to our database through the below fomular and we'll let you know if we initiate one that suits you.<\/p><p>More about our <a href=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2024\/04\/Ensayos_clinicos_vacunas.pdf\">studies<\/a>.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-9c4ef6c\" data-id=\"9c4ef6c\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b1bc4c2 elementor-view-default elementor-widget elementor-widget-icon\" data-id=\"b1bc4c2\" data-element_type=\"widget\" data-widget_type=\"icon.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-icon-wrapper\">\n\t\t\t<div class=\"elementor-icon\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" id=\"Layer_1\" x=\"0px\" y=\"0px\" viewbox=\"0 0 100.75 100.75\" style=\"enable-background:new 0 0 100.75 100.75;\" xml:space=\"preserve\"><path d=\"M86.549,81.743H48.396c-0.02-0.001-0.038-0.006-0.058-0.006c-14.229,0-25.807-11.577-25.807-25.807  c0-6.878,2.763-13.477,7.621-18.307c1.636,1.503,3.734,2.346,5.972,2.372c0.034,0,0.069,0,0.104,0c1.87,0,3.651-0.577,5.153-1.634  l7.495,7.675c0.294,0.301,0.684,0.452,1.073,0.452c0.378,0,0.756-0.142,1.048-0.427l1.547-1.51l4.214,4.327  c0.277,0.285,0.657,0.448,1.055,0.453c0.007,0,0.013,0,0.02,0c0.392,0,0.768-0.153,1.048-0.426l5.383-5.252  c0.284-0.278,0.447-0.658,0.452-1.056s-0.148-0.781-0.427-1.066l-4.22-4.323l1.257-1.226c0.284-0.278,0.447-0.657,0.452-1.055  c0.005-0.397-0.148-0.781-0.427-1.066L37.824,9.755c-0.046-0.047-0.098-0.085-0.149-0.125c-0.04-0.054-0.06-0.117-0.109-0.167  c-3.307-3.352-8.77-3.373-12.184-0.042c-3.363,3.299-3.5,8.673-0.339,12.051c0.071,0.17,0.168,0.331,0.305,0.471l3.635,3.722  c-1.117,1.509-1.741,3.318-1.762,5.228c-0.018,1.547,0.358,3.036,1.074,4.36c-5.577,5.412-8.761,12.882-8.761,20.677  c0,11.301,6.544,21.097,16.038,25.813H15.916c-0.828,0-1.5,0.671-1.5,1.5v8.322c0,0.829,0.672,1.5,1.5,1.5h70.635  c0.828,0,1.5-0.671,1.5-1.5v-8.322C88.049,82.415,87.377,81.743,86.549,81.743z M61.094,42.553l-3.234,3.156l-3.169-3.253  l3.23-3.153L61.094,42.553z M27.479,11.565c1.952-1.903,4.923-2.142,7.076-0.715l-7.95,7.768  C25.227,16.439,25.533,13.474,27.479,11.565z M36.724,12.924l21.432,21.958l-8.182,7.985L28.541,20.92L36.724,12.924z   M39.246,36.176c-0.92,0.543-1.97,0.833-3.089,0.819c-1.604-0.018-3.104-0.66-4.228-1.81c-1.122-1.145-1.729-2.657-1.711-4.257  c0.013-1.105,0.33-2.158,0.898-3.076L39.246,36.176z M85.049,90.065H17.414v-5.322h67.635V90.065z\"><\/path><path d=\"M61.811,70.137c0.296,0.315,0.695,0.475,1.096,0.475c0.367,0,0.735-0.134,1.024-0.404l22.25-20.812  c0.605-0.566,0.637-1.516,0.071-2.121c-0.567-0.605-1.516-0.636-2.12-0.071l-22.25,20.812  C61.277,68.583,61.246,69.532,61.811,70.137z\"><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-17e08e8\" data-id=\"17e08e8\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d7467c1 elementor-widget elementor-widget-heading\" data-id=\"d7467c1\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">\/<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-f7edee6\" data-id=\"f7edee6\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-cd5d3a5 elementor-view-default elementor-widget elementor-widget-icon\" data-id=\"cd5d3a5\" data-element_type=\"widget\" data-widget_type=\"icon.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-icon-wrapper\">\n\t\t\t<div class=\"elementor-icon\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" id=\"Layer_1\" x=\"0px\" y=\"0px\" viewbox=\"0 0 100.4 100.4\" style=\"enable-background:new 0 0 100.4 100.4;\" xml:space=\"preserve\"><style type=\"text\/css\">\t.st0{fill:none;stroke:#2BACE2;stroke-width:0.3528;stroke-miterlimit:10;}\t.st1{fill:none;stroke:#EC2227;stroke-width:0.3528;stroke-miterlimit:10;}<\/style><g>\t<g>\t\t<g>\t\t\t<path class=\"st0\" d=\"M100,6.7\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,13.3\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,20\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,26.7\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,33.3\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,40\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,46.7\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,53.3\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,60\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,66.7\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,73.3\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,80\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,86.7\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,93.3\"><\/path>\t\t\t<path class=\"st0\" d=\"M100,100\"><\/path>\t\t<\/g>\t\t<path class=\"st1\" d=\"M100,6.7\"><\/path>\t\t<path class=\"st1\" d=\"M100,93.3\"><\/path>\t<\/g><\/g><path d=\"M84.2,92L72.7,69c-0.6-1.1-0.7-1.4-1-2L57.4,38.5V17.2h6.2c0.8,0,1.5-0.7,1.5-1.5V8c0-0.8-0.7-1.5-1.5-1.5H32.8  c-0.8,0-1.5,0.7-1.5,1.5v7.7c0,0.8,0.7,1.5,1.5,1.5H39v21.2L24.7,67c-0.3,0.6-0.5,1.1-1,2L12.2,92c-0.2,0.5-0.2,1,0.1,1.5  s0.8,0.7,1.3,0.7h69.3c0.5,0,1-0.3,1.3-0.7S84.4,92.5,84.2,92z M41.8,39.5c0.1-0.2,0.2-0.4,0.2-0.7V15.7c0-0.8-0.7-1.5-1.5-1.5h-6.2  V9.5h27.8v4.7h-6.2c-0.8,0-1.5,0.7-1.5,1.5v23.1c0,0.2,0.1,0.5,0.2,0.7l14.1,28.1c-0.5,0.3-0.8,0.6-1.2,0.8c-0.6,0.5-1,0.8-2,0.8  s-1.3-0.3-2-0.8c-0.8-0.6-1.9-1.5-3.8-1.5c-2,0-3,0.9-3.8,1.5c-0.6,0.5-1,0.8-1.9,0.8c-0.9,0-1.3-0.3-1.9-0.8  c-0.8-0.6-1.9-1.5-3.8-1.5c-2,0-3,0.9-3.8,1.5c-0.6,0.5-1,0.8-1.9,0.8s-1.3-0.3-1.9-0.8c-0.8-0.6-1.9-1.5-3.8-1.5s-3,0.9-3.8,1.5  c-0.6,0.5-1,0.8-1.9,0.8s-1.3-0.3-1.9-0.8c-0.3-0.3-0.7-0.6-1.2-0.8L41.8,39.5z M16,91.2l10.4-20.9c0.2,0.1,0.4,0.3,0.6,0.5  c0.8,0.6,1.9,1.5,3.8,1.5c2,0,3-0.9,3.8-1.5c0.6-0.5,1-0.8,1.9-0.8s1.3,0.3,1.9,0.8c0.8,0.6,1.9,1.5,3.8,1.5s3-0.9,3.8-1.5  c0.6-0.5,1-0.8,1.9-0.8c0.9,0,1.3,0.3,1.9,0.8c0.8,0.6,1.9,1.5,3.8,1.5c2,0,3-0.9,3.8-1.5c0.6-0.5,1-0.8,1.9-0.8  c0.9,0,1.3,0.3,2,0.8c0.8,0.6,1.9,1.5,3.8,1.5s3-0.9,3.8-1.5c0.2-0.2,0.4-0.3,0.6-0.5l10.4,20.9H16z\"><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a626886 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a626886\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-54b61e1\" data-id=\"54b61e1\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b2de648 ee-toggle-element--stack-mobile ee-toggle-element--round ee-labels-align--center ee-labels-align-stacked--center elementor-widget elementor-widget-ee-toggle-element\" data-id=\"b2de648\" data-element_type=\"widget\" data-settings=\"{&quot;indicator_color&quot;:&quot;#6EC1E4&quot;,&quot;toggle_active_index&quot;:1,&quot;indicator_speed&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:0.3,&quot;sizes&quot;:[]},&quot;refresh_widgets&quot;:&quot;yes&quot;}\" data-widget_type=\"ee-toggle-element.classic\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"ee-toggle-element\">\n\t\t\t<div class=\"ee-toggle-element__toggle\">\n\t\t\t\t<div class=\"ee-toggle-element__controls-wrapper ee-toggle-element__controls-wrapper--before\">\n\t\t\t<div class=\"ee-toggle-element__indicator\"><\/div><ul class=\"ee-toggle-element__controls\"><li class=\"ee-toggle-element__controls__item elementor-repeater-item-731590f ee--is-empty\" data-hash=\"731590f\"><span class=\"ee-toggle-element__controls__text\" unselectable=\"on\">Recruitment phase<\/span><\/li><li class=\"ee-toggle-element__controls__item elementor-repeater-item-4fe2c39 ee--is-empty\" data-hash=\"4fe2c39\"><span class=\"ee-toggle-element__controls__text\" unselectable=\"on\">Active testing<\/span><\/li><li class=\"ee-toggle-element__controls__item elementor-repeater-item-f7d91e3 ee--is-empty\" data-hash=\"f7d91e3\"><span class=\"ee-toggle-element__controls__text\" unselectable=\"on\">Historical<\/span><\/li><\/ul><\/div>\t\t\t\t<div class=\"ee-toggle-element__elements\">\n\t\t\t\t\t<div class=\"ee-toggle-element__element elementor-repeater-item-731590f\"><div id=\"gtx-trans\" style=\"position: absolute; left: 62px; top: 1589.39px;\"><div class=\"gtx-trans-icon\">\u00a0<\/div><div><div><div>\u00a0<\/div><\/div><div>\u00a0<\/div><\/div><\/div><div><h3><strong>Actualmente no tenemos ninguno en fase de reclutamiento.<\/strong><\/h3><\/div><div id=\"gtx-trans\" style=\"position: absolute; left: 62px; top: 1589.39px;\"><div class=\"gtx-trans-icon\">\u00a0<\/div><div><div><div>\u00a0<\/div><\/div><div>\u00a0<\/div><\/div><\/div><\/div><div class=\"ee-toggle-element__element elementor-repeater-item-4fe2c39\"><h3><strong>Gripe<\/strong><\/h3><p><strong>Title:<\/strong> Estudio en fase III, aleatorizado, con enmascaramiento para el evaluador, comparativo con tratamiento activo, en adultos \u2265 60 a\u00f1os de edad para evaluar la seguridad y la inmunogenia de la vacuna antigripal en dosis altas experimental de Abbott<br \/><strong>Protocol code:<\/strong> INFQ-324-0476<br \/><strong>N\u00ba EudraCT:<\/strong> 2024-519743-15-00<br \/><strong>A qui\u00e9n va dirigido<\/strong>: personas que hayan participado en el estudio RSV OA=ADJ-006<br \/><strong>Centre where it takes place:<\/strong> FOM (Fundaci\u00f3n Oftalmol\u00f3gica del Mediterr\u00e1neo).<\/p><h3><strong>Herpes Z\u00f3ster:<\/strong><\/h3><p><strong>Title: <\/strong><span class=\"ui-provider vw b c d e f g h i j k l m n o p q r s t u v w x y z ab ac ae af ag ah ai aj ak\" dir=\"ltr\">Estudio en fase IIIb, multic\u00e9ntrico, internacional, abierto, de seguimiento a largo plazo de ZOSTER-049 (seguimiento de los estudios ZOSTER-006\/022) para evaluar la eficacia profil\u00e1ctica, la seguridad y la persistencia de la respuesta inmunitaria de una vacuna de subunidades de herpes z\u00f3ster y para evaluar la persistencia de la respuesta inmunitaria y la seguridad de 1 o 2 dosis adicionales<br \/>administradas en ZOSTER-049 en 2 subgrupos de adultos de edad avanzada\u201d de fase 3b.<\/span><br \/><strong>Protocol code: <\/strong><span class=\"ui-provider vw b c d e f g h i j k l m n o p q r s t u v w x y z ab ac ae af ag ah ai aj ak\" dir=\"ltr\"> 217917 (ZOSTER-101)<\/span><br \/><strong>N\u00ba EudraCT:<\/strong> <span class=\"ui-provider vw b c d e f g h i j k l m n o p q r s t u v w x y z ab ac ae af ag ah ai aj ak\" dir=\"ltr\">2021-005319-30<\/span><br \/><strong>Years:<\/strong> 2023-2027<\/p><p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05371080?term=2021-005319-30&amp;draw=2&amp;rank=1\" target=\"_blank\" rel=\"noopener\">See study<\/a><\/p><div><h3><strong>Virus Respiratorio Sincitial:<\/strong><\/h3><\/div><div><p><strong>Title:<\/strong> Estudio Fase IIIb, aleatorizado, abierto, multinacional, multic\u00e9ntrico, de extensi\u00f3n y vacunaci\u00f3n cruzada para evaluar la inmunogenicidad y seguridad de diferentes pautas de revacunaci\u00f3n, as\u00ed como la persistencia de una dosis \u00fanica de la vacuna RSVPreF3 OA en adultos de 60 a\u00f1os o m\u00e1s de edad que participaron en el estudio RSV OA=ADJ-006\u201d<br \/><strong>Protocol code:<\/strong> 222090 (RSV OA=ADJ-012)<br \/><strong>N\u00ba EudraCT:<\/strong> 2023-509762-38-00<br \/><strong>Who it is aimed at:<\/strong> Personas adultas a partir de 60 a\u00f1os de edad que hayan participado en el estudio RSV OA=ADJ-006<br \/><strong>Centre where it takes place:<\/strong> FOM (Fundaci\u00f3n Oftalmol\u00f3gica del Mediterr\u00e1neo)<\/p><p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06534892?id=2023-509762-38-00&amp;rank=1\" target=\"_blank\" rel=\"noopener\">See study<\/a><\/p><\/div><div><p>\u00a0<\/p><\/div><\/div><div class=\"ee-toggle-element__element elementor-repeater-item-f7d91e3\"><div><div><p><strong>T\u00edtulo<\/strong>: Estudio de fase 3 en abierto, aleatorizado, comparativo y realizado en varios pa\u00edses para evaluar la respuesta inmunitaria, la seguridad y la reactogenia de la vacuna en investigaci\u00f3n contra el virus respiratorio sincitial de prote\u00edna 3 de prefusi\u00f3n en adultos mayores (VRSPreF3 OA) cuando se administra simult\u00e1neamente con una vacuna antineumoc\u00f3cica conjugada icosavalente (PCV20) en adultos mayores de 60 a\u00f1os.<br \/><strong>Protocol code:<\/strong> 219276<br \/><strong>N\u00ba EudraCT: <\/strong><span class=\"ui-provider fz b c d e f g h i j k l m n o p q r s t u v w x y z ab ac ae af ag ah ai aj ak\" dir=\"ltr\">2022-501988-40-00<\/span><br \/><strong>Who it is aimed at:<\/strong> <span class=\"ui-provider fz b c d e f g h i j k l m n o p q r s t u v w x y z ab ac ae af ag ah ai aj ak\" dir=\"ltr\">Personas adultas de 60 a\u00f1os en adelante.<\/span><br \/><strong>Centre where it takes place:<\/strong> Fundaci\u00f3n Oftalmolog\u00eda M\u00e9dica de la Comunitat Valenciana (FOM)<\/p><p><strong>Title:<\/strong> Estudio de\u00a0fase 2\/3, aleatorizado, con observador ciego y controlado con placebo para evaluar la seguridad\u00a0y la eficacia de mRNA-1345, una vacuna de ARNm contra el virus respiratorio sincitial (VRS), en personas adultas\u00a0a partir de 60 a\u00f1os de edad.<br \/><strong>Protocol code: <\/strong>mRNA-1345-P301<br \/><strong>N\u00ba EudraCT:\u00a0<\/strong>2021-005026-20<br \/><strong>Who it is aimed at:<\/strong>\u00a0Personas adultas\u00a0a partir de 60 a\u00f1os de edad.<br \/><strong>Centre where it takes place:<\/strong> FISABIO-Oftalmolog\u00eda M\u00e9dica<\/p><p><strong>Title: <\/strong>Estudio cl\u00ednico de fase 3, aleatorizado, doble ciego y controlado con comparador activo para evaluar la seguridad, tolerabilidad e inmunogenicidad de V116 en adultos de 50 a\u00f1os en adelante sin exposici\u00f3n previa a vacunas antineumoc\u00f3cicas.<br \/><strong>Protocol code: <\/strong>V116-010<br \/><strong>N\u00ba EudraCT: <\/strong>2022-001785-35<br \/><strong>Who it is aimed at: <\/strong>Personas adultas de 50 a\u00f1os en adelante.<br \/><strong>Centre where it takes place:\u00a0<\/strong>FISABIO-Oftalmolog\u00eda M\u00e9dica (FOM)<\/p><p><strong>Title:\u00a0<\/strong>Estudio de fase III, multinacional, observador ciego, aleatorizado,\u00a0controlado con placebo para demostrar la eficacia de una dosis \u00fanica de la vacuna en\u00a0investigaci\u00f3n RSVPreF3 OA de GSK en adultos de 60 a\u00f1os o m\u00e1s de edad.<br \/><strong>Protocol code:\u00a0<\/strong>212494 (RSV OA=ADJ-006)<br \/><strong>N\u00ba EudraCT:\u00a0<\/strong>2020-000753-28<br \/><strong>Who it is aimed at: <\/strong>Adultos de 60 a\u00f1os o m\u00e1s<br \/><strong>Centre where it takes place:\u00a0<\/strong>FISABIO-Oftalmolog\u00eda M\u00e9dica (FOM)<\/p><p><strong>Title:\u00a0<\/strong>Phase III, multicentre, randomized, blinded observer, placebo-controlled clinical trial to evaluate herpes zoster recurrence and the reactogenicity, safety, and immunogenicity of GSK Biologicals herpes zoster (HZ\/su) vaccine when administered intramuscularly in a 0 and 2-month pattern to adults aged 50 years or older with a previous episode of herpes zoster.<br \/><strong>Protocol code:\u00a0<\/strong>204939 (ZOSTER-062)<br \/><strong>EudraCT number:\u00a0<\/strong>2016-000744-34<br \/><strong>To whom it is directed:<\/strong>\u00a0People over 50 years of age.<br \/><strong>Centre where it takes place:<\/strong>\u00a0FOM-Fisabio<\/p><p><strong>Title:<\/strong> Estudio de cohortes no aleatorizado, abierto e internacional para describir la seguridad de las participantes que recibieron o la vacuna para inmunizaci\u00f3n materna RSVPreF3 (cualquier dosis) o el placebo (grupo control) en los estudios RSV MAT anteriores (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 y RSV MAT-039), durante cualquier embarazo posterior a la vacunaci\u00f3n con la vacuna RSVPreF3 o el placebo.<br \/><strong>Protocol code:<\/strong> 219510 (RSV MAT-015)<br \/><strong>N\u00ba EudraCT:<\/strong> 2022-003124-41<br \/><strong>Who it is aimed at:<\/strong> Participantes anteriores estudios RSV-MAT<br \/><strong>Centre where it takes place:<\/strong>\u00a0FISABIO-Oftalmolog\u00eda M\u00e9dica (FOM)<\/p><p><strong>Title:<\/strong> Inmunogenicidad y seguridad de la vacuna de prote\u00ednas recombinantes de SARS-CoV-2 con adyuvante AS03 en adultos de 18 a\u00f1os en adelante como serie primaria, e inmunogenicidad y seguridad de una dosis de recuerdo de vacunas de prote\u00ednas recombinantes de SARS-CoV-2 con adyuvante (dos monovalentes y una bivalente)<br \/><strong>Protocol code:<\/strong> VAT00002<br \/><strong>N\u00ba EudraCT:<\/strong> 2020-003370-41<br \/><strong>Who it is aimed at:<\/strong> Adultos a partir de 18 a\u00f1os<br \/><strong>Centre where it takes place:<\/strong>\u00a0FISABIO-Oftalmolog\u00eda M\u00e9dica (FOM)<\/p><p><strong>Title:<\/strong>\u00a0Estudio de fase 3, aleatorizado, doble ciego,\u00a0controlado con comparador activo y de consistencia entre lotes, para evaluar la seguridad, la tolerabilidad y la inmunogenicidad de V116 en adultos de 18 a 49 a\u00f1os<br \/><strong>Protocol code:\u00a0<\/strong>V116-004<br \/><strong>N\u00ba EudraCT:\u00a0<\/strong>2022-000265-41<br \/><strong>Who it is aimed at:<\/strong>\u00a0Personas adultas\u00a0de entre 18 y 49 a\u00f1os.<br \/><strong>Centre where it takes place:<\/strong> FISABIO-Oftalmolog\u00eda M\u00e9dica<\/p><p><strong>Title:<\/strong> Efficacy, safety, and immunogenicity of GSK Biologicals' HZ\/su vaccine GSK1437173A is a phase IIIb, open-label, long-term follow-up study (ZOE-LTFU) of studies 110390\/113077 (ZOSTER-006\/022) and evaluation of additional doses in older adults\".<br \/><strong>Protocol code:\u00a0<\/strong>201190 (ZOSTER-049)<strong>\u00a0<\/strong><br \/><strong>N\u00ba EudraCT:<\/strong>\u00a0 2015-001778-17<br \/><strong>Years:<\/strong>\u00a02016-2023<\/p><p><strong>Title:<\/strong> Phase IIb, open-label clinical trial to assess the safety, tolerability, and immunogenicity of MenABCWY in healthy 2- and 6-month-old infants.<br \/><strong>Protocol code:<\/strong> C3511002<br \/><strong>N\u00ba EudraCT: <\/strong>2020-000948-60<br \/><strong>Who it is aimed at:<\/strong>\u00a0Children between 2 and 6 months.<br \/><strong>Centre where it takes place:<\/strong> Serrer\u00eda II, Eliana, Paiporta, Nazaret.<\/p><p><strong>Title:<\/strong> Ensayo en fase III, alaeatorizado, doble ciego para evaluar la seguridad de una vacuna antineumoc\u00f3cica 20-valente en lactantes sanos<br \/><strong>Protocol code:<\/strong> B7471013<br \/><strong>EudraCT number: <\/strong>2019-003307-35<br \/><strong>Who it is aimed at:<\/strong>\u00a0Breastfed children from 42 days to 98 days<br \/><strong>Centers where it is done:<\/strong> Burriana II, Eliana, Malvarrosa, Paiporta y Serrer\u00eda II.<\/p><p><strong>Title: <\/strong>Estudio fase III, observador-ciego, aleatorizado, internacional para evaluar la consistencia de lotes de la vacuna candidata de GSK para inmunizaci\u00f3n materna frente al VRS, as\u00ed como, la respuesta inmune, seguridad y reactogenicidad de esta vacuna candidata de GSK frente al VRS en coadministraci\u00f3n con la vacuna tetravalente D-QIV de GSK frente a gripe, en mujeres sanas no embarazadas de 18 a 49 a\u00f1os.<br \/><strong>Protocol code: <\/strong>214709 (RSV MAT 010)<br \/><strong>N\u00ba EudraCT: <\/strong>2021-000357-26<br \/><strong>Who it is aimed at: <\/strong>Mujeres de 18-49 a\u00f1os de edad.<br \/><strong>Centre where it takes place:\u00a0<\/strong>FISABIO-Oftalmolog\u00eda M\u00e9dica (FOM)<\/p><p><strong style=\"font-size: 16px;\">Title:<\/strong><span style=\"font-size: 16px;\">\u00a0Estudio\u00a0<\/span><a style=\"font-size: 16px;\" href=\"https:\/\/estudiovigira.es\/\" target=\"_blank\" rel=\"noopener\">VIGIRA<\/a><span style=\"font-size: 16px;\">Phase IV, randomized, double-blind, controlled clinical trial of seasonal influenza vaccine in children aged 12-35 months to estimate efficacy against influenza and other respiratory infections.<br \/><\/span><strong>EudraCT number:<\/strong> 2019-001186-33<br \/><strong>Centre where it takes place:<\/strong> CS Serrer\u00eda I, CS Serrer\u00eda II, CS de Nazaret, CS Trafalgar, CS L\u2019Eliana, CS Ontinyent, CS Trinitat, Cl\u00ednica Privada Gabriel Ruiz, CS Guillem De Castro, CS Torrent II, CS Puerto de Sagunto, y CS Burriana II (Castell\u00f3n), CS Alboraia, CS Benic\u00e0ssim, CS Fernando el Cat\u00f3lico (Castell\u00f3n), CS El Grao (Castell\u00f3n), Hospital General Universitario de Castell\u00f3n, Hospital Lluis Alcany\u00eds (X\u00e0tiva), CS Navarr\u00e9s, CS Napoles i Sicilia.<\/p><p><strong>Title:<\/strong> Estudio de inmunogenia y seguridad de una vacuna conjugada antimeningoc\u00f3cica tetravalente con respecto a Nimenrix\u00ae, y cuando se administra sola o de manera concomitante con las vacunas 9vHPV y Tdap-IPV en adolescentes<br \/>sanos.<br \/><strong>Protocol code: <\/strong>MEQ00071<\/p><div><strong>N\u00ba EudraCT: <\/strong>2020-001665-37<\/div><div><p><strong>Centre where it takes place: <\/strong>Serrer\u00eda I, Serrer\u00eda II, Burriana II, Nazaret, Malvarrosa y Puzol.<\/p><\/div><p><strong>Title:<\/strong> Phase 3, multicentre, randomized, double-blind, controlled study with an active comparator drug to assess the safety, tolerability, and immunogenicity of V114 in healthy infants (PNEU-PED-EU- 1)<br \/><strong>Protocol code:<\/strong> V114-025<br \/><strong>Centre where it takes place:<\/strong> CS Malvarrosa, CS Serrer\u00eda II, CS L\u2019Eliana, CS Paiporta, and CS de Nazaret.<\/p><p><strong>Title:\u00a0<\/strong>Study to evaluate the safety, reactogenicity, and immunogenicity of GSK Biologicals' experimental respiratory syncytial virus (RSV) vaccine based on viral proteins encoded by a chimpanzee-derived adenovector (ChAd155 RSV) (GSK3389245A) in infants<br \/><strong>Protocol code:<\/strong> 204894 (RSV-PED-011)<br \/><strong>EudraCT number: <\/strong>2018-000431-27<br \/><strong>Center in which it is carried out:<\/strong> Nazaret, Paiporta, Malvarrosa<\/p><p><strong>Title:<\/strong> Study to evaluate the safety, reactogenicity, and immunogenicity of GSK Biologicals' experimental respiratory syncytial virus (RSV) vaccine based on viral proteins encoded by a chimpanzee-derived adenovector (ChAd155 RSV) (GSK3389245A) in VRS-positive children.<br \/><strong>Promoter: <\/strong>GlaxoSmithKline, S.A.<br \/><strong>EudraCT number:<\/strong> 2016-000117-76<br \/><strong>Years:<\/strong>\u00a02016-2020<\/p><p><strong>Title:<\/strong> Immunogenicity, reactogenicity, and safety study of different formulations of GSK Biologicals' ACWY conjugate meningitis vaccine (GSK3536820A and Menveo) administered to healthy adolescents and young adults aged 10 to 40 years.<br \/><strong>Promoter:<\/strong>\u00a0GlaxoSmithKline 207467 (MENACWY CONJ-069 [V59_78])<br \/><strong>EudraCT number:<\/strong> 2017-003456-23<br \/><strong>Years:\u00a0<\/strong>2018-2019<\/p><p><strong>Title:<\/strong> Cross-vaccination study with the freeze-dried formulation of the Herpes Zoster subunit vaccine (HZ\/su) from GSK Biologicals (GSK 1437173A) in subjects who previously received a placebo in the ZOSTER-006 and ZOSTER- 022 studies.<br \/><strong>Protocol:<\/strong>\u00a0204486 (ZOSTER-056)<br \/><strong>EudraCT number:\u00a0<\/strong>2015-000965-30<br \/><strong>Promoter:\u00a0<\/strong>GlaxoSmithKline, S.A.<br \/><strong>Years:\u00a0<\/strong>2016-2018<\/p><p><strong>Title:<\/strong> Phase IIIA, multicentre, randomized, blinded observer study to assess the consistency of three production batches of the liquid formulation of the rotavirus-attenuated human oral vaccine (NVR)<br \/><strong>Protocol:<\/strong>\u00a0115461 (Rota-081)<br \/><strong>EudraCT number:\u00a0<\/strong>2016-000598-19<br \/><strong>Promoter:<\/strong>\u00a0GlaxoSmithKline, S.A.<br \/><strong>Years:<\/strong>\u00a02017-2019<\/p><p><strong>Title:<\/strong> Phase III multinational, observer-blind, randomized, controlled study with parallel-group, non-influenza vaccine comparators in children aged 6-35 months to evaluate the safety and efficacy of<br \/>Abbott's experimental quadrivalent flu vaccine\".<br \/><strong>Protocol:<\/strong>\u00a0INFQ3003<br \/><strong>EudraCT number:<\/strong>\u00a02016-004904-74<br \/><strong>Promoter:\u00a0<\/strong>Abbott Biologicals B.V.<br \/><strong>Years:\u00a0<\/strong>2017-2019<\/p><p><strong>Title:<\/strong>\u00a0 Phase 3, multicentre, randomized, double-blind, controlled study with an active comparator to assess the safety, tolerability, and immunogenicity of V114 followed by the administration, one year later, of PNEUMOVAX\u212223 in healthy adults aged 50 years and over (PNEU-PATH)<br \/><strong>Protocol:<\/strong>\u00a0V114 &#8211; 016<br \/><strong>EudraCT number:<\/strong> 2017-004024-30<br \/><strong>Promoter:\u00a0<\/strong>Merck Sharp &amp; Dohme<br \/><strong>Years:\u00a0<\/strong>2018-2019<\/p><p><strong>Title:<\/strong> Efficacy, safety, and immunogenicity study of GSK Biologicals Herpes Zoster vaccine GSK1437173A in adults 50 years and older.<br \/><strong>Protocol:\u00a0<\/strong>110390. Z\u00f3ster 006.<br \/><strong>EudraCT Number<\/strong>: 2008-000367-42.<br \/><strong>Promoter:<\/strong>\u00a0GlaxoSmithKline<br \/><strong>Years:<\/strong> 2010-2014<\/p><p><strong>Title:<\/strong> Efficacy, safety, and immunogenicity study of GSK Biologicals Herpes Zoster vaccine GSK1437173A in adults 70 years and older.<br \/><strong>Code:<\/strong>\u00a0113077. Z\u00f3ster 022.<br \/><strong>EudraCT number:<\/strong> 2009-015791-94.<br \/><strong>Protocol:\u00a0<\/strong>GlaxoSmithKline<br \/><strong>Years:<\/strong> 2010-2014<\/p><p><strong>Title:<\/strong> Phase IIIb, randomized, open-label study to assess the feasibility of priming with a single dose of group C meningococcal conjugate vaccine (NeisVac-C) in infants<br \/><strong>Protocol:\u00a0<\/strong>670901<br \/><strong>EudraCT number:<\/strong> 2010-019383-36<br \/><strong>Promoter:<\/strong> Baxter Innovations GmbH<br \/><strong>Years:<\/strong> 2010-2012<\/p><p><strong>Title:<\/strong> Multi-centre, double-blind study of the safety, tolerability, and immunogenicity of a pneumococcal conjugate vaccine (V114) compared with Prevent 13\u2122 in healthy infants.<br \/><strong>Protocol:<\/strong>\u00a0V114-003 <strong>EudraCT number:<\/strong> 2010-019775-29<br \/><strong>Promoter:\u00a0<\/strong>Merck Sharp &amp; Dohme<br \/><strong>Years:<\/strong> 2010-2012<\/p><p><strong>Title:<\/strong> A randomized, double-blind, controlled phase III clinical trial using GARDASIL\u00ae (human papillomavirus [types 6, 11, 16, 18] vaccine (recombinant, adsorbed)) to study the immunogenicity and tolerability of V503 (9-valent human papillomavirus [HPV] L1 particle vaccine [VLP]) in pre-adolescent and adolescent girls (9-15 years of age).<br \/><strong>Protocol:<\/strong>\u00a0GDS01C<\/p><p><strong>EudraCT number:<\/strong> 2010-023393-39<br \/><strong>Promoter:<\/strong> Sanofi Pasteur MSD<br \/><strong>Years:<\/strong> 2010-2012<\/p><p><strong>Title:<\/strong> A randomized, placebo-controlled, single-blind phase 2 study to evaluate the safety, tolerability, and immunogenicity of the rLP2086 vaccine when administered in a 2- or 3-dose schedule to healthy older subjects \u226511 to \u2264 19 years<br \/><strong>Protocol:<\/strong>\u00a0B1971012. <strong>EudraCT number:<\/strong> 2009-014493-18<br \/><strong>Promoter:<\/strong>\u00a0Pfizer<br \/><strong>Years:<\/strong> 2010-2012<\/p><p><strong>Title:<\/strong> Open, multicentre, randomized and comparative study of the immunogenicity and safety of ZOSTAVAX\u00ae, when administered intramuscularly or subcutaneously to subjects &gt;50 years of age<br \/><strong>Protocol:<\/strong>\u00a0ZTV03C<br \/><strong>EudraCT number:<\/strong> 2009-012458-19<br \/><strong>Promoter:<\/strong> Sanofi Pasteur MSD<br \/><strong>Years:<\/strong> 2011-2012<\/p><p><strong>Title:<\/strong> Phase III, blinded, randomized, multinational, controlled study with a non-influenza vaccine to demonstrate the efficacy of GSK Biologicals' quadrivalent seasonal influenza vaccine GSK2321138A (FLU D-QIV), administered intramuscularly in children 6-35 months of age<br \/><strong>Protocol:<\/strong>\u00a0115345 (FLU D-QIV-004 PRI)<br \/><strong>EudraCT number:<\/strong> 2011-000758-41<br \/><strong>Promoter:\u00a0<\/strong>GlaxoSmithKline<br \/><strong>Years:<\/strong> 2011-2013<\/p><p><strong>Title:\u00a0<\/strong>Multi-centre, double-blind study of the safety, tolerability, and immunogenicity of a pneumococcal conjugate vaccine (V114) compared with a polysaccharide pneumococcal vaccine (PNEUMOVAX\u212223) and Prevent 13\u2122 (13-valent pneumococcal conjugate vaccine [diphtheria protein CRM197]) in healthy adults aged 50 years or older.<br \/><strong>Protocol:\u00a0<\/strong>V114-002 <strong>EudraCT number:<\/strong> 2011-004542-18<br \/><strong>Promoter:<\/strong>\u00a0MSD<br \/><strong>Year:<\/strong> 2012<\/p><p><strong>Title:<\/strong> Phase 3, open-label, multi-center extension study to assess antibody persistence and response to a third or fifth dose of Novartis recombinant meningococcal B vaccine in 4-year-old children who previously participated in the V72P12E1 study.<br \/><strong>Protocol:<\/strong>\u00a0V72P12E2<\/p><p><strong>EudraCT number:<\/strong> 2011-004931-30<br \/><strong>Promoter:<\/strong>\u00a0Novartis<br \/><strong>Year:<\/strong> 2013<\/p><p><strong>Title:<\/strong> Immunogenicity, safety and reactogenicity study of GSK Biologicals' quadrivalent seasonal influenza vaccine GSK2321138A administered to children who have previously participated in the 115345 study<br \/><strong>Protocol:\u00a0<\/strong>116023 (FLU D-QIV-009 ext 004)<br \/><strong>EudraCT number:<\/strong> 2012-001230-34<br \/><strong>Promoter:<\/strong>\u00a0GlaxoSmithKline<br \/><strong>Years:<\/strong> 2012-2013<\/p><p><strong>Title:<\/strong> Double-blind, randomized, controlled, multi-center study to assess the safety, tolerability, and immunogenicity of a new formulation of RotaTeq\u2122<br \/><strong>Protocol:<\/strong>\u00a0V260-035<\/p><p><strong>EudraCT number:<\/strong> 2012-001611-23<br \/><strong>Promoter:<\/strong> Merck Sharp &amp; Dohme<br \/><strong>Years:<\/strong> 2013-2014<\/p><p><strong>Title:<\/strong> Phase III, multicentre, randomized, blinded observer study to assess the safety of trivalent subunit influenza vaccines produced in mammalian cell culture (ccTV) or in embryonated eggs (ETV) in children and adolescents aged 3 to &lt; 18 years at risk of influenza-related complications<br \/><strong>Protocol:\u00a0<\/strong>V58P15<br \/><strong>EudraCT number:<\/strong>\u00a02013-002080-26<br \/><strong>Promoter:<\/strong>\u00a0Novartis<br \/><strong>Years:<\/strong> 2013-2014<\/p><p><strong>Title:<\/strong> Phase III open study to evaluate the immunogenicity and safety of an alternating primary vaccination schedule (HEXA\/PENTA\/HEXA) including V419 (PR5I) at 2 and 6 months of age and PediacelR at 4 months of age<br \/><strong>Protocol:\u00a0<\/strong>PRI02C<br \/><strong>EudraCT number:<\/strong>\u00a02012-004221-25<br \/><strong>Promoter:<\/strong>\u00a0Sanofi Pasteur MSD<br \/><strong>Years:<\/strong> 2013-2014<\/p><p><strong>Title:\u00a0<\/strong>Phase 3, masked observer, placebo-controlled, randomized trial to assess the safety, tolerability, and immunogenicity of the bivalent rLP2086 vaccine when administered in a 3-dose regimen to healthy young adults aged between \u226518 and &lt; 26 years<br \/><strong>Protocol:<\/strong>\u00a0B1971016 (6108A1-2004).<br \/><strong>EudraCT number:\u00a0<\/strong>2009-014492-46<br \/><strong>Promoter:<\/strong> Pfizer<br \/><strong>Years:<\/strong> 2013-2015<\/p><p><strong>Title: <\/strong>Immunogenicity and safety study of GSK Biologicals' Priorix\u00ae vaccine (209762) with end-of-life potency compared to Merck &amp; Co., Inc., administered according to a 2-dose pattern to healthy children in the 2nd year of life<br \/><strong>Protocol:\u00a0<\/strong>115649 (MMR-161)<br \/><strong>EudraCT number:<\/strong>\u00a02011-004905-26<br \/><strong>Promoter:<\/strong>\u00a0GlaxoSmithKline<br \/><strong>Years:<\/strong> 2013-2015<\/p><p><strong>Title:<\/strong> Batch consistency study of GSK Biologicals' MMR vaccine (209762) (Priorix\u00ae) comparing immunogenicity and safety with Merck &amp; Co. (M-M-R\u00aeII) in healthy children aged 12-15 months<br \/><strong>Protocol:<\/strong>\u00a0115648 (MMR-160)<br \/><strong>EudraCT number:<\/strong>\u00a02011-004891-12<br \/><strong>Promoter:\u00a0<\/strong>GlaxoSmithKline<br \/><strong>Years:<\/strong> 2013-2015<\/p><p><strong>Title:<\/strong> Phase 3, randomized, placebo-controlled, active vaccine trial with the blinded observer to assess the safety, tolerability, and immunogenicity of a recombinant serogroup B meningococcal lipoprotein vaccine (rLP2086) administered to healthy subjects from \u226510 to &lt; 26 years<br \/><strong>Protocol:\u00a0<\/strong>B1971014<\/p><p><strong>EudraCT number:\u00a0<\/strong>2009-015198-11<br \/><strong>Promoter:\u00a0<\/strong>Pfizer<br \/><strong>Years:<\/strong> 2013-2014<\/p><p><strong>Title:<\/strong> Immunogenicity and safety study of a combined hexavalent DTaP-IPV-HB-Hib vaccine in a primary series of 3 doses in healthy infants in Europe.<br \/><strong>Protocol:<\/strong>\u00a0A3L39<br \/><strong>EudraCT number:<\/strong>\u00a02012-001055-39<br \/><strong>Promoter:<\/strong>\u00a0Sanofi Pasteur<br \/><strong>Years:<\/strong> 2014-2015<\/p><p><strong>Title:<\/strong> Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multi-Purpose L1 Particle Viroid (PV) Vaccine against Human Papillomavirus (HPV), administered to Pre-Adolescents and Adolescents (9-14 years) compared with Young Women (16-26 years).<br \/><strong>Protocol:<\/strong> V503-010\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <strong>EudraCT number:<\/strong> 2013-001314-15<br \/><strong>Promoter:\u00a0<\/strong>Merck Sharp &amp;Dohme<br \/><strong>Years:<\/strong> 2014- 2017<\/p><p><strong>Title:<\/strong> Reminder and safety effect of a combined DTaPIPV- Hib vaccine, with or without Hep B vaccination, in healthy subjects 11-18 months of age who received a combined hexavalent or hexavalent\/pentavalent vaccine during the primary series<br \/><strong>Protocol:<\/strong>\u00a0A3L40<br \/><strong>N\u00famero <\/strong><strong>EudraCT:\u00a0<\/strong>2012-001042-18<br \/><strong>Promoter:<\/strong>\u00a0Sanofi Pasteur<br \/><strong>Years:<\/strong> 2014-2016<\/p><p><strong>Title:<\/strong> Phase III, multicentre, randomized, blinded observer study (except in the trivalent influenza vaccine [TIV] groups, which will be open), placebo-controlled, conducted in healthy children aged 6-35 months<br \/><strong>Protocol:<\/strong>\u00a0GQM05<br \/><strong>EudraCT number:<\/strong> 2013-001231-51<br \/><strong>Promoter:<\/strong>\u00a0Sanofi Pasteur<br \/><strong>Years:<\/strong> 2014-2017<\/p><\/div><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-602174c elementor-section-height-min-height elementor-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-items-middle\" data-id=\"602174c\" data-element_type=\"section\" id=\"interesa\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;,&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-ac39adc\" data-id=\"ac39adc\" data-element_type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-dbc1529 elementor-widget elementor-widget-heading\" data-id=\"dbc1529\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">Sign up for our database<\/h4>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-79b08b0 elementor-button-align-stretch elementor-invisible elementor-widget elementor-widget-form\" data-id=\"79b08b0\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;,&quot;step_next_label&quot;:&quot;Next&quot;,&quot;step_previous_label&quot;:&quot;Previous&quot;,&quot;button_width&quot;:&quot;100&quot;,&quot;step_type&quot;:&quot;number_text&quot;,&quot;step_icon_shape&quot;:&quot;circle&quot;}\" data-widget_type=\"form.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<form class=\"elementor-form\" method=\"post\" name=\"New Form\">\n\t\t\t<input type=\"hidden\" name=\"post_id\" value=\"1635\"\/>\n\t\t\t<input type=\"hidden\" name=\"form_id\" value=\"79b08b0\"\/>\n\t\t\t<input type=\"hidden\" name=\"referer_title\" value=\"\" \/>\n\n\t\t\t\n\t\t\t<div class=\"elementor-form-fields-wrapper elementor-labels-above\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-text elementor-field-group elementor-column elementor-field-group-name elementor-col-33 elementor-md-100\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<input size=\"1\" type=\"text\" name=\"form_fields[name]\" id=\"form-field-name\" class=\"elementor-field elementor-size-xs  elementor-field-textual\" placeholder=\"Name\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-email elementor-field-group elementor-column elementor-field-group-email elementor-col-33 elementor-md-100 elementor-field-required elementor-mark-required\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<input size=\"1\" type=\"email\" name=\"form_fields[email]\" id=\"form-field-email\" class=\"elementor-field elementor-size-xs  elementor-field-textual\" placeholder=\"Email\" required=\"required\" aria-required=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-tel elementor-field-group elementor-column elementor-field-group-field_dc06f22 elementor-col-33 elementor-md-100\">\n\t\t\t\t\t\t\t<input size=\"1\" type=\"tel\" name=\"form_fields[field_dc06f22]\" id=\"form-field-field_dc06f22\" class=\"elementor-field elementor-size-xs  elementor-field-textual\" placeholder=\"Telephone\" pattern=\"[0-9()#&amp;+*-=.]+\" title=\"Only numbers and phone characters (#, -, *, etc) are accepted.\">\n\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-date elementor-field-group elementor-column elementor-field-group-field_bd9dd7b elementor-col-33 elementor-md-100 elementor-field-required elementor-mark-required\">\n\t\t\t\t\t\n\t\t<input type=\"date\" name=\"form_fields[field_bd9dd7b]\" id=\"form-field-field_bd9dd7b\" class=\"elementor-field elementor-size-xs  elementor-field-textual elementor-date-field\" placeholder=\"Fecha de nacimiento\" required=\"required\" aria-required=\"true\" pattern=\"[0-9]{4}-[0-9]{2}-[0-9]{2}\">\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-acceptance elementor-field-group elementor-column elementor-field-group-field_78c0878 elementor-col-100 elementor-field-required elementor-mark-required\">\n\t\t\t\t\t\t\t<div class=\"elementor-field-subgroup\">\n\t\t\t<span class=\"elementor-field-option\">\n\t\t\t\t<input type=\"checkbox\" name=\"form_fields[field_78c0878]\" id=\"form-field-field_78c0878\" class=\"elementor-field elementor-size-xs  elementor-acceptance-field\" required=\"required\" aria-required=\"true\">\n\t\t\t\t<label for=\"form-field-field_78c0878\">I accept the privacy policy<\/label>\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-text\">\n\t\t\t\t\t<input size=\"1\" type=\"text\" name=\"form_fields[field_f9063a9]\" id=\"form-field-field_f9063a9\" class=\"elementor-field elementor-size-xs\" style=\"display:none !important;\">\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-group elementor-column elementor-field-type-submit elementor-col-100 e-form__buttons\">\n\t\t\t\t\t<button class=\"elementor-button elementor-size-sm\" type=\"submit\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Send<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/button>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<input type=\"hidden\" name=\"trp-form-language\" value=\"eng\"\/><\/form>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-06f8496 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"06f8496\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-11036a2\" data-id=\"11036a2\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a50c49a elementor-widget-divider--view-line_text elementor-widget-divider--element-align-left elementor-widget elementor-widget-divider\" data-id=\"a50c49a\" data-element_type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t\t<span class=\"elementor-divider__text elementor-divider__element\">\n\t\t\t\tThe importance of clinical trials\t\t\t\t<\/span>\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-792c282 elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"792c282\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-87a89f0\" data-id=\"87a89f0\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-698ec92 elementor-widget elementor-widget-text-editor\" data-id=\"698ec92\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>Concern about vaccine safety has contributed to the development of appropriate methods for evaluating the potential benefits and risks of vaccines.<\/p><p>It is inconceivable to register a new medicine without clinical studies that evaluate its efficacy and the safety of its use.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-06c73e6\" data-id=\"06c73e6\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-84e1f17 elementor-widget elementor-widget-image\" data-id=\"84e1f17\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/image_gallery-1-1024x683.jpg\" class=\"attachment-large size-large wp-image-188\" alt=\"\" srcset=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/image_gallery-1-1024x683.jpg 1024w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/image_gallery-1-300x200.jpg 300w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/image_gallery-1-768x512.jpg 768w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/image_gallery-1-1536x1024.jpg 1536w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/image_gallery-1-2048x1365.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-937af51 elementor-section-content-middle elementor-reverse-mobile elementor-reverse-tablet elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"937af51\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-2cb643b\" data-id=\"2cb643b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c5807b4 elementor-widget elementor-widget-image\" data-id=\"c5807b4\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"950\" height=\"600\" data-src=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W.jpg\" class=\"attachment-large size-large wp-image-1870 lazyload\" alt=\"\" data-srcset=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W.jpg 950w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W-300x189.jpg 300w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W-768x485.jpg 768w\" data-sizes=\"(max-width: 950px) 100vw, 950px\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 950px; --smush-placeholder-aspect-ratio: 950\/600;\" \/><noscript><img decoding=\"async\" width=\"950\" height=\"600\" src=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W.jpg\" class=\"attachment-large size-large wp-image-1870\" alt=\"\" srcset=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W.jpg 950w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W-300x189.jpg 300w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W-768x485.jpg 768w\" sizes=\"(max-width: 950px) 100vw, 950px\" \/><\/noscript>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-bd60f57\" data-id=\"bd60f57\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4d36f4c elementor-widget elementor-widget-text-editor\" data-id=\"4d36f4c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>Any new drug is thoroughly researched in the laboratory and tested on animals before approved for use in humans. However, it is clear that animal research, also called preclinical research, has significant limitations when applied to the study of human diseases.<\/p><p>Conducting studies with humans allows us to know the needs and effects of vaccines, specifically, in our bodies.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-938e53f elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"938e53f\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-84f995a\" data-id=\"84f995a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b9f7de5 elementor-widget elementor-widget-text-editor\" data-id=\"b9f7de5\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>The importance of clinical trials is indisputable. Thanks to the people who test the candidate product, it is possible to determine if it is safe and effective to administer it to a part of the population. Without the participation of these people, many curable diseases today would continue to be lethal.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-4040754\" data-id=\"4040754\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-13fd095 elementor-widget elementor-widget-image\" data-id=\"13fd095\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1024\" height=\"680\" data-src=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-1024x680.jpg\" class=\"attachment-large size-large wp-image-346 lazyload\" alt=\"\" data-srcset=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-1024x680.jpg 1024w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-300x199.jpg 300w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-768x510.jpg 768w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-1536x1020.jpg 1536w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-2048x1360.jpg 2048w\" data-sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/680;\" \/><noscript><img decoding=\"async\" width=\"1024\" height=\"680\" src=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-1024x680.jpg\" class=\"attachment-large size-large wp-image-346\" alt=\"\" srcset=\"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-1024x680.jpg 1024w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-300x199.jpg 300w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-768x510.jpg 768w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-1536x1020.jpg 1536w, https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/06\/DSC_0128-2048x1360.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/noscript>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-43d2f90 elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"43d2f90\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-9ae9a0e\" data-id=\"9ae9a0e\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c3b05ec elementor-widget-divider--view-line_text elementor-widget-divider--element-align-left elementor-widget elementor-widget-divider\" data-id=\"c3b05ec\" data-element_type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t\t<span class=\"elementor-divider__text elementor-divider__element\">\n\t\t\t\tFrequently Asked Questions\t\t\t\t<\/span>\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-585faf33 elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"585faf33\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-865c69b\" data-id=\"865c69b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-119d055e elementor-widget elementor-widget-accordion\" data-id=\"119d055e\" data-element_type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-2951\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-2951\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">\u00bfPara qu\u00e9 sirven los ensayos cl\u00ednicos en vacunas?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2951\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-2951\"><p>Son la manera m\u00e1s segura y r\u00e1pida de encontrar vacunas que ayuden a mejorar la salud de las personas.\u00a0<\/p><p>Los resultados son importantes porque proporcionan m\u00e1s informaci\u00f3n sobre los riesgos y beneficios de las vacunas en estudio.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-2952\" class=\"elementor-tab-title\" data-tab=\"2\" role=\"button\" aria-controls=\"elementor-tab-content-2952\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">\u00bfCu\u00e1les son las fases de un ensayos cl\u00ednico?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2952\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"region\" aria-labelledby=\"elementor-tab-title-2952\"><p>Fase I: Permite entender c\u00f3mo el f\u00e1rmaco act\u00faa en el cuerpo, y c\u00f3mo el cuerpo reacciona frente al f\u00e1rmaco (c\u00f3mo se absorbe, se distribuye y se metaboliza). Generalmente se estudia en un peque\u00f1o grupo de voluntarios sanos.<\/p><p>Fase II: Eval\u00faa la eficacia del f\u00e1rmaco, y por lo tanto se lleva a cabo en un grupo de participantes mayor. En esta fase se eval\u00faan los efectos adversos a corto plazo y los riesgos de seguridad asociados al f\u00e1rmaco en investigaci\u00f3n.<\/p><p>Fase III: Confirma la seguridad y los beneficios terap\u00e9uticos del nuevo f\u00e1rmaco o combinaci\u00f3n de \u00e9stos en un grupo mayor de pacientes. Si los resultados son positivos, se solicita la autorizaci\u00f3n del f\u00e1rmaco para uso cl\u00ednico.<\/p><p>Fase IV: Son los estudios que se realizan una vez el f\u00e1rmaco est\u00e1 en el mercado y por tanto en una poblaci\u00f3n mucho mayor. Est\u00e1n dise\u00f1ados para evaluar la seguridad y eficacia del f\u00e1rmaco a largo plazo.<\/p><p>El \u00c1rea de Investigaci\u00f3n en Vacunas trabaja principalmente en ensayos en fase III y IV.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-2953\" class=\"elementor-tab-title\" data-tab=\"3\" role=\"button\" aria-controls=\"elementor-tab-content-2953\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">\u00bfQu\u00e9 tengo que hacer para participar?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2953\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"region\" aria-labelledby=\"elementor-tab-title-2953\"><p>Debe cumplir los requisitos de reclutamiento. El equipo le informar\u00e1 sobre ello.<\/p><p>Una vez haya tomado la decisi\u00f3n de participar, ser\u00e1 informado de forma clara y minuciosa de toda la informaci\u00f3n relativa al estudio, incluyendo los beneficios y riesgos y dem\u00e1s datos relevantes.<\/p><p>As\u00ed mismo, tendr\u00e1 que firmar un consentimiento informado dejando constancia de que ha sido informado de forma adecuada de todo lo correspondiente al ensayo y se le har\u00e1 entrega de una copia de este documento para que en cualquier momento usted pueda consultarlo.<\/p><p>El equipo le acompa\u00f1ar\u00e1 en todo este proceso, resolviendo cualquier pregunta o haciendo cualquier aclaraci\u00f3n que necesite.\u00a0<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-2954\" class=\"elementor-tab-title\" data-tab=\"4\" role=\"button\" aria-controls=\"elementor-tab-content-2954\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">\u00bfCu\u00e1les son los principales beneficios y riesgos de participar en un ensayo cl\u00ednico?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2954\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"region\" aria-labelledby=\"elementor-tab-title-2954\"><p>Beneficios<\/p><ul><li>Recibir una nueva vacuna o tratamiento que todav\u00eda no ha salido al mercado.<\/li><li>Seguimiento peri\u00f3dico de su salud.<\/li><li>Desempe\u00f1ar un papel activo en investigaci\u00f3n.<\/li><\/ul><p>Risks<\/p><ul><li>Posibilidad de que surjan acontecimientos adversos.<\/li><li><span style=\"font-family: var( --e-global-typography-text-font-family ), Sans-serif;\">El tratamiento puede no ser eficaz.<\/span><\/li><li>La participaci\u00f3n puede requerir una dedicaci\u00f3n de tiempo y esfuerzo.<\/li><\/ul><p>Las personas que est\u00e9n considerando participar en un estudio, pueden comentar los riesgos y los beneficios del estudio\u00a0con el equipo de investigaci\u00f3n.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-2955\" class=\"elementor-tab-title\" data-tab=\"5\" role=\"button\" aria-controls=\"elementor-tab-content-2955\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">How is my privacy respected?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2955\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"5\" role=\"region\" aria-labelledby=\"elementor-tab-title-2955\"><p>Cuando el participante entra en el estudio, se le asigna un n\u00famero y todos sus datos quedan asociados a \u00e9l para que su informaci\u00f3n est\u00e9 protegida.\u00a0<\/p><p><span style=\"font-family: var( --e-global-typography-text-font-family ), Sans-serif;\">Adem\u00e1s, todos los datos del estudio son confidenciales. S\u00f3lo el equipo investigador tiene acceso a ellos.<\/span><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-bfe761d\" data-id=\"bfe761d\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-949c616 elementor-widget elementor-widget-accordion\" data-id=\"949c616\" data-element_type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1551\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-1551\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Do you pay to participate?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1551\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-1551\"><p>En Espa\u00f1a la legislaci\u00f3n s\u00f3lo permite pagar peque\u00f1as compensaciones por las molestias y el desplazamiento. La cuant\u00eda de la compensaci\u00f3n estar\u00e1 en relaci\u00f3n con las caracter\u00edsticas del ensayo, pero nunca ser\u00e1 tan elevada como para inducir a una persona a participar por motivos econ\u00f3micos.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1552\" class=\"elementor-tab-title\" data-tab=\"2\" role=\"button\" aria-controls=\"elementor-tab-content-1552\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">\u00bfSon seguros los ensayos cl\u00ednicos?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1552\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"region\" aria-labelledby=\"elementor-tab-title-1552\"><p>S\u00ed. Los tratamientos han sido ampliamente probados en ensayos de laboratorio antes de que sean estudiados en la poblaci\u00f3n.\u00a0<\/p><p><span style=\"font-family: var( --e-global-typography-text-font-family ), Sans-serif;\">Cada uno de los planes del estudio (protocolo) es inspeccionado y debe ser aprobado por un comit\u00e9 \u00e9tico, para garantizar su seguridad y buena pr\u00e1ctica.<\/span><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1553\" class=\"elementor-tab-title\" data-tab=\"3\" role=\"button\" aria-controls=\"elementor-tab-content-1553\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">How do I find out the results of the trial?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1553\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"region\" aria-labelledby=\"elementor-tab-title-1553\"><p>Puede solicitar los resultados del estudio al equipo investigador.<\/p><p>Adem\u00e1s, existe una obligaci\u00f3n de publicar los resultados obtenidos de los ensayos cl\u00ednicos.\u00a0\u00a0<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1554\" class=\"elementor-tab-title\" data-tab=\"4\" role=\"button\" aria-controls=\"elementor-tab-content-1554\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">\u00bfPuedo abandonar el ensayo?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1554\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"region\" aria-labelledby=\"elementor-tab-title-1554\"><p>Puede retirarse de un ensayo en cualquier momento. No tiene que dar una raz\u00f3n para hacerlo y en ning\u00fan caso le perjudicar\u00e1 a la hora de recibir su trato m\u00e9dico habitual.<\/p><p>Sin embargo, esta informaci\u00f3n le sirve al equipo para solucionar cualquier incidente dentro del proceso y mejorar en un futuro.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-1555\" class=\"elementor-tab-title\" data-tab=\"5\" role=\"button\" aria-controls=\"elementor-tab-content-1555\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-chevron-down\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-chevron-up\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Who can participate in a trial?<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1555\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"5\" role=\"region\" aria-labelledby=\"elementor-tab-title-1555\"><p>Cualquier persona de cualquier edad que cumpla los criterios espec\u00edficos del estudio (edad, proximidad del centro donde se realiza, etc.)<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Ensayos cl\u00ednicos Los ensayos cl\u00ednicos en vacunas son estudios que se llevan a cabo para saber si una vacuna es eficaz y segura.\u00a0 A continuaci\u00f3n, encuentra un listado de los estudios en los que estamos trabajando: en fase de reclutamiento, activos y pasados.\u00a0 Si no encuentras ninguno que te interese, siempre puedes apuntarte a nuestra &#8230; <a title=\"Clinical Trials\" class=\"read-more\" href=\"https:\/\/aivfisabio.com\/eng\/ensayos-clinicos\/\" aria-label=\"Read more about Ensayos cl\u00ednicos\">Read more<\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"class_list":["post-1635","page","type-page","status-publish"],"rankMath":{"parentDomain":"aivfisabio.com","noFollowDomains":[],"noFollowExcludeDomains":[],"noFollowExternalLinks":false,"featuredImageNotice":"The featured image should be at least 200 by 200 pixels to be picked up by Facebook and other social media sites.","pluginReviewed":false,"postSettings":{"linkSuggestions":true,"useFocusKeyword":false},"frontEndScore":false,"postName":"ensayos-clinicos","permalinkFormat":"https:\/\/aivfisabio.com\/eng\/%pagename%\/","showLockModifiedDate":true,"assessor":{"focusKeywordLink":"https:\/\/aivfisabio.com\/wp-admin\/edit.php?focus_keyword=%focus_keyword%&post_type=%post_type%","hasTOCPlugin":true,"primaryTaxonomy":false,"serpData":{"title":"","description":"","focusKeywords":"ensayos cl\u00ednicos","pillarContent":false,"canonicalUrl":"","breadcrumbTitle":"","advancedRobots":{"max-snippet":"-1","max-video-preview":"-1","max-image-preview":"large"},"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":"","facebookHasOverlay":false,"facebookImageOverlay":"","facebookAuthor":"","twitterCardType":"","twitterUseFacebook":true,"twitterTitle":"","twitterDescription":"","twitterImage":"","twitterImageID":"","twitterHasOverlay":false,"twitterImageOverlay":"","twitterPlayerUrl":"","twitterPlayerSize":"","twitterPlayerStream":"","twitterPlayerStreamCtype":"","twitterAppDescription":"","twitterAppIphoneName":"","twitterAppIphoneID":"","twitterAppIphoneUrl":"","twitterAppIpadName":"","twitterAppIpadID":"","twitterAppIpadUrl":"","twitterAppGoogleplayName":"","twitterAppGoogleplayID":"","twitterAppGoogleplayUrl":"","twitterAppCountry":"","robots":{"index":true},"twitterAuthor":"username","primaryTerm":0,"authorName":"admin","titleTemplate":"%title% %sep% %sitename%","descriptionTemplate":"%excerpt%","showScoreFrontend":true,"lockModifiedDate":false},"powerWords":["a cut above","absolute","absolutely","absolutely lowest","absurd","abuse","accurate","accuse","achieve","actionable","adaptable","adequate","admit","adorable","advantage","advice","affordable","aggravate","aggressive","agitated","agonizing","agony","alarmed","alarming","alienated","aligned","alive","all-inclusive","alluring","always","amazing","amp","animated","annihilate","announcing","anonymous","antagonistic","anxious","apocalypse","appalled","approved","approving","argumentative","armageddon","arrogant","ass kicking","assault","assured","astonishing","astounded","astounding","at ease","atrocious","attack","attractive","audacity","authentic","authoritative","authority","avoid","aware","awe-inspiring","awesome","awkward","backbone","backdoor","backed","backlash","backstabbing","badass","balanced","banned","bargain","barrage","basic","battle","beaming","beat down","beating","beautiful","beauty","begging","behind the scenes","belief","belong","best","best-selling","better","beware","big","billion","black market","blacklisted","blast","blessed","blinded","blissful","blood","bloodbath","bloodcurdling","bloody","blunder","blushing","bold","bomb","bona","bona fide","bonanza","bonus","bootleg","bottom line","bountiful","brave","bravery","brazen","break","breaking","breakthrough","breathtaking","bright","brilliant","broke","brutal","budget","buffoon","bullshit","bully","bumbling","buy","cadaver","calm","cancel anytime","capable","captivate","captivating","carefree","case study","cash","cataclysmic","catapult","catastrophe","caution","censored","centered","certain","certainly","certified","challenge","charming","cheap","cheat","cheat-sheet","cheer","cheerful","child-like","clarity","classified","clear","clueless","collapse","colorful","colossal","comfortable","compare","competitive","complete","completely","completeness","comprehensive","compromise","compulsive","concealed","conclusive","condemning","condescending","confess","confession","confessions","confident","confidential","conquer","conscientious","constructive","content","contrary","controlling","controversial","convenient","convert","cool","cooperative","copy","corpse","corrupt","corrupting","courage","courageous","cover-up","covert","coward","cowardly","crammed","crave","crazy","create","creative","cringeworthy","cripple","crisis","critical","crooked","crush","crushing","damaging","danger","dangerous","daring","dazzling","dead","deadline","deadly","death","decadent","deceived","deceptive","deep","defiance","definitely","definitive","defying","dejected","delicious","delight","delighted","delightful","delirious","delivered","demoralizing","deplorable","depraved","desire","desperate","despicable","destiny","destroy","detailed","devastating","devoted","diagnosed","direct","dirty","disadvantages","disastrous","discount","discover","disdainful","disempowered","disgusted","disgusting","dishonest","disillusioned","disoriented","distracted","distraught","distressed","distrustful","divulge","document","dollar","dominate","doomed","double","doubtful","download","dreadful","dreamy","drive","drowning","dumb","dynamic","eager","earnest","easily","easy","economical","ecstatic","edge","effective","efficient","effortless","elated","eliminate","elite","embarrass","embarrassed","embarrassing","emergency","emerging","emphasize","empowered","enchant","encouraged","endorsed","energetic","energy","enormous","enraged","enthusiastic","envy","epic","epidemic","essential","ethical","euphoric","evil","exactly","exasperated","excellent","excited","excitement","exciting","exclusive","exclusivity","excruciating","exhilarated","expensive","expert","explode","exploit","explosive","exposed","exquisite","extra","extraordinary","extremely","exuberant","eye-opening","fail","fail-proof","failure","faith","famous","fantasy","fascinating","fatigued","faux","faux pas","fearless","feast","feeble","festive","fide","fierce","fight","final","fine","fired","first","first ever","flirt","fluid","focus","focused","fool","fooled","foolish","forbidden","force-fed","forever","forgiving","forgotten","formula","fortune","foul","frantic","free","freebie","freedom","frenzied","frenzy","frightening","frisky","frugal","frustrated","fulfill","fulfilled","full","fully","fun","fun-loving","fundamentals","funniest","funny","furious","gambling","gargantuan","genius","genuine","gift","gigantic","giveaway","glamorous","gleeful","glorious","glowing","goddamn","gorgeous","graceful","grateful","gratified","gravity","great","greatest","greatness","greed","greedy","gripping","grit","grounded","growth","guaranteed","guilt","guilt-free","gullible","guts","hack","happiness","happy","harmful","harsh","hate","have you heard","havoc","hazardous","healthy","heart","heartbreaking","heartwarming","heavenly","hell","helpful","helplessness","hero","hesitant","hidden","high tech","highest","highly effective","hilarious","hoak","hoax","honest","honored","hope","hopeful","horribly","horrific","horrifying","horror","hostile","how to","huge","humility","humor","hurricane","hurry","hypnotic","idiot","ignite","illegal","illusive","imagination","immediately","imminently","impatience","impatient","impenetrable","important","impressive","improved","in the zone","incapable","incapacitated","incompetent","inconsiderate","increase","incredible","indecisive","indulgence","indulgent","inexpensive","inferior","informative","infuriated","ingredients","innocent","innovative","insane","insecure","insider","insidious","inspired","inspiring","instant savings","instantly","instructive","insult","intel","intelligent","intense","interesting","intriguing","introducing","invasion","investment","iron-clad","ironclad","irresistible","irs","is here","jackpot","jail","jaw-dropping","jealous","jeopardy","jittery","jovial","joyous","jubilant","judgmental","jumpstart","just arrived","keen","kickass","kickstart","kill","killed","killing","kills","know it all","lame","largest","lascivious","last","last chance","last minute","latest","laugh","laughing","launch","launching","lavishly","lawsuit","lazy","left behind","legendary","legitimate","liberal","liberated","lick","lies","life-changing","lifetime","light","lighthearted","likely","limited","literally","little-known","loathsome","lonely","looming","loser","lost","love","lucrative","lunatic","lurking","lust","luxurious","luxury","lying","magic","magical","magnificent","mainstream","malicious","mammoth","manipulative","marked down","massive","master","masterclass","maul","mediocre","meditative","meltdown","memorability","memorable","menacing","mesmerizing","meticulous","mind-blowing","minimalist","miracle","mired","mischievous","misgiving","missing out","mistake","monetize","money","moneyback","moneygrubbing","monumental","most important","motivated","mouth-watering","murder","mystery","nail","naked","natural","naughty","nazi","nest egg","never","new","nightmare","no good","no obligation","no one talks about","no questions asked","no risk","no strings attached","non-controlling","noted","novelty","now","obnoxious","obsessed","obsession","obvious","odd","off-kilter","off-limits","off-the record","offensive","official","okay","on-demand","open-minded","opportunities","optimistic","ordeal","outlawed","outrageousness","outstanding","overcome","overjoyed","overnight","overwhelmed","packed","painful","painless","painstaking","pale","panic","panicked","paralyzed","pas","passionate","pathetic","pay zero","payback","perfect","peril","perplexed","perspective","pessimistic","pioneering","piranha","pitfall","pitiful","placid","plague","played","playful","pleased","pluck","plummet","plunge","poison","poisonous","polarizing","poor","popular","portfolio","pound","powerful","powerless","practical","preposterous","prestige","price","priceless","pride","prison","privacy","private","privileged","prize","problem","productive","professional","profit","profitable","profound","promiscuous","promising","promote","protect","protected","proven","provocative","provoke","psychological","pummel","punch","punish","pus","quadruple","quality","quarrelsome","quick","quick-start","quickly","quiet","radiant","rare","ravenous","rebellious","recession-proof","reckoning","recognized","recommend","recreate","reduced","reflective","refugee","refund","refundable","reject","relaxed","release","relentless","reliable","remarkable","replicate","report","reprimanding","repulsed","repulsive","research","resentful","resourceful","responsible","responsive","rested","restricted","results","retaliating","reveal","revealing","revenge","revengeful","revisited","revolting","revolutionary","reward","rich","ridiculous","risky","riveting","rookie","rowdy","ruin","rules","ruthless","sabotaging","sacred","sadistic","sadly","sadness","safe","safety","sale","sampler","sarcastic","satisfied","savage","savagery","save","savings","savvy","scam","scandal","scandalous","scarce","scared","scary","scornful","scream","searing","secret","secret agenda","secret plot","secrets","secure","security","seductive","seething","seize","selected","self-hating","self-sufficient","sensational","senseless","sensual","serene","seriously","severe","sex","sexy","shaking","shameful","shameless","shaming","shatter","shellacking","shocking","should","shrewd","sick and tired","signs","silly","simple","simplicity","simplified","simplistic","sincere","sinful","sins","six-figure","sizable","sizzle","sizzled","sizzles","sizzling","sizzlingly","skill","skyrocket","slaughter","slave","sleazy","sleeping","sly","smash","smiling","smug","smuggle","smuggled","sneak-peek","sneaky","sniveling","snob","snooty","snotty","soar","soaring","solid","solution","spank","special","spectacular","speedy","spell-binding","spine","spirit","spirited","spiteful","spoiler","spontaneous","spotlight","spunky","squirming","stable","staggering","startling","steady","steal","stealthy","steamy","step-by-step","still","stoic","stop","strange","strangle","strategy","stressed","strong","strongly suggest","struggle","stuck up","studies","stunning","stupid","stupid-simple","sturdy","sublime","succeed","success","successful","suck","suddenly","suffer","sunny","super","super-human","superb","supercharge","superior","supported","supportive","sure","sure fire","surefire","surge","surging","surprise","surprised","surprising","survival","survive","suspicious","sweaty","swoon","swoon-worthy","tailspin","tank","tantalizing","targeted","tawdry","tease","technology","teetering","tempting","tenacious","tense","terrible","terrific","terrified","terrifying","terror","terrorist","tested","thankful","the truth","threaten","threatened","thrilled","thrilling","thug","ticked off","tickled","timely","today","torture","toxic","track record","trade secret","tragedy","tragic","transform","transparency","trap","trapped","trauma","traumatized","treacherous","treasure","tremendous","trend","tricks","triggers","triple","triumph","truly","trusting","trustworthy","truth","truthful","turbo-charge","turbocharges","tweaks","twitching","ultimate","unadulterated","unassuming","unauthorized","unbelievable","unburdened","uncaring","uncensored","uncertain","uncomfortable","unconditional","uncontrollable","unconventional","uncovered","undeniable","under priced","undercover","underground","underhanded","underused","unexpected","unforgettable","unheard of","unhurried","uninterested","unique","unjustified","unknowingly","unleashed","unlimited","unlock","unparalleled","unpopular","unreliable","unresponsive","unseen","unstable","unstoppable","unsure","unsurpassed","untapped","unusual","up-sell","upbeat","uplifted","uplifting","urge","urgent","useful","useless","validate","valor","valuable","value","vanquish","vaporize","venomous","verify","vibrant","vicious","victim","victory","vigorous","vilified","vindictive","violated","violent","volatile","vulnerable","waiting","wanted","wanton","warning","waste","weak","wealth","weird","what no one tells you","whip","whopping","wicked","wild","willpower","withheld","wonderful","wondrous","woozy","world","worry","worst","worthwhile","wounded","wreaking","youthful","zen","zinger"],"diacritics":{"A":"[\\u0041\\u24B6\\uFF21\\u00C0\\u00C1\\u00C2\\u1EA6\\u1EA4\\u1EAA\\u1EA8\\u00C3\\u0100\\u0102\\u1EB0\\u1EAE\\u1EB4\\u1EB2\\u0226\\u01E0\\u00C4\\u01DE\\u1EA2\\u00C5\\u01FA\\u01CD\\u0200\\u0202\\u1EA0\\u1EAC\\u1EB6\\u1E00\\u0104\\u023A\\u2C6F]","AA":"[\\uA732]","AE":"[\\u00C6\\u01FC\\u01E2]","AO":"[\\uA734]","AU":"[\\uA736]","AV":"[\\uA738\\uA73A]","AY":"[\\uA73C]","B":"[\\u0042\\u24B7\\uFF22\\u1E02\\u1E04\\u1E06\\u0243\\u0182\\u0181]","C":"[\\u0043\\u24B8\\uFF23\\u0106\\u0108\\u010A\\u010C\\u00C7\\u1E08\\u0187\\u023B\\uA73E]","D":"[\\u0044\\u24B9\\uFF24\\u1E0A\\u010E\\u1E0C\\u1E10\\u1E12\\u1E0E\\u0110\\u018B\\u018A\\u0189\\uA779]","DZ":"[\\u01F1\\u01C4]","Dz":"[\\u01F2\\u01C5]","E":"[\\u0045\\u24BA\\uFF25\\u00C8\\u00C9\\u00CA\\u1EC0\\u1EBE\\u1EC4\\u1EC2\\u1EBC\\u0112\\u1E14\\u1E16\\u0114\\u0116\\u00CB\\u1EBA\\u011A\\u0204\\u0206\\u1EB8\\u1EC6\\u0228\\u1E1C\\u0118\\u1E18\\u1E1A\\u0190\\u018E]","F":"[\\u0046\\u24BB\\uFF26\\u1E1E\\u0191\\uA77B]","G":"[\\u0047\\u24BC\\uFF27\\u01F4\\u011C\\u1E20\\u011E\\u0120\\u01E6\\u0122\\u01E4\\u0193\\uA7A0\\uA77D\\uA77E]","H":"[\\u0048\\u24BD\\uFF28\\u0124\\u1E22\\u1E26\\u021E\\u1E24\\u1E28\\u1E2A\\u0126\\u2C67\\u2C75\\uA78D]","I":"[\\u0049\\u24BE\\uFF29\\u00CC\\u00CD\\u00CE\\u0128\\u012A\\u012C\\u0130\\u00CF\\u1E2E\\u1EC8\\u01CF\\u0208\\u020A\\u1ECA\\u012E\\u1E2C\\u0197]","J":"[\\u004A\\u24BF\\uFF2A\\u0134\\u0248]","K":"[\\u004B\\u24C0\\uFF2B\\u1E30\\u01E8\\u1E32\\u0136\\u1E34\\u0198\\u2C69\\uA740\\uA742\\uA744\\uA7A2]","L":"[\\u004C\\u24C1\\uFF2C\\u013F\\u0139\\u013D\\u1E36\\u1E38\\u013B\\u1E3C\\u1E3A\\u0141\\u023D\\u2C62\\u2C60\\uA748\\uA746\\uA780]","LJ":"[\\u01C7]","Lj":"[\\u01C8]","M":"[\\u004D\\u24C2\\uFF2D\\u1E3E\\u1E40\\u1E42\\u2C6E\\u019C]","N":"[\\u004E\\u24C3\\uFF2E\\u01F8\\u0143\\u00D1\\u1E44\\u0147\\u1E46\\u0145\\u1E4A\\u1E48\\u0220\\u019D\\uA790\\uA7A4]","NJ":"[\\u01CA]","Nj":"[\\u01CB]","O":"[\\u004F\\u24C4\\uFF2F\\u00D2\\u00D3\\u00D4\\u1ED2\\u1ED0\\u1ED6\\u1ED4\\u00D5\\u1E4C\\u022C\\u1E4E\\u014C\\u1E50\\u1E52\\u014E\\u022E\\u0230\\u00D6\\u022A\\u1ECE\\u0150\\u01D1\\u020C\\u020E\\u01A0\\u1EDC\\u1EDA\\u1EE0\\u1EDE\\u1EE2\\u1ECC\\u1ED8\\u01EA\\u01EC\\u00D8\\u01FE\\u0186\\u019F\\uA74A\\uA74C]","OI":"[\\u01A2]","OO":"[\\uA74E]","OU":"[\\u0222]","P":"[\\u0050\\u24C5\\uFF30\\u1E54\\u1E56\\u01A4\\u2C63\\uA750\\uA752\\uA754]","Q":"[\\u0051\\u24C6\\uFF31\\uA756\\uA758\\u024A]","R":"[\\u0052\\u24C7\\uFF32\\u0154\\u1E58\\u0158\\u0210\\u0212\\u1E5A\\u1E5C\\u0156\\u1E5E\\u024C\\u2C64\\uA75A\\uA7A6\\uA782]","S":"[\\u0053\\u24C8\\uFF33\\u1E9E\\u015A\\u1E64\\u015C\\u1E60\\u0160\\u1E66\\u1E62\\u1E68\\u0218\\u015E\\u2C7E\\uA7A8\\uA784]","T":"[\\u0054\\u24C9\\uFF34\\u1E6A\\u0164\\u1E6C\\u021A\\u0162\\u1E70\\u1E6E\\u0166\\u01AC\\u01AE\\u023E\\uA786]","TZ":"[\\uA728]","U":"[\\u0055\\u24CA\\uFF35\\u00D9\\u00DA\\u00DB\\u0168\\u1E78\\u016A\\u1E7A\\u016C\\u00DC\\u01DB\\u01D7\\u01D5\\u01D9\\u1EE6\\u016E\\u0170\\u01D3\\u0214\\u0216\\u01AF\\u1EEA\\u1EE8\\u1EEE\\u1EEC\\u1EF0\\u1EE4\\u1E72\\u0172\\u1E76\\u1E74\\u0244]","V":"[\\u0056\\u24CB\\uFF36\\u1E7C\\u1E7E\\u01B2\\uA75E\\u0245]","VY":"[\\uA760]","W":"[\\u0057\\u24CC\\uFF37\\u1E80\\u1E82\\u0174\\u1E86\\u1E84\\u1E88\\u2C72]","X":"[\\u0058\\u24CD\\uFF38\\u1E8A\\u1E8C]","Y":"[\\u0059\\u24CE\\uFF39\\u1EF2\\u00DD\\u0176\\u1EF8\\u0232\\u1E8E\\u0178\\u1EF6\\u1EF4\\u01B3\\u024E\\u1EFE]","Z":"[\\u005A\\u24CF\\uFF3A\\u0179\\u1E90\\u017B\\u017D\\u1E92\\u1E94\\u01B5\\u0224\\u2C7F\\u2C6B\\uA762]","a":"[\\u0061\\u24D0\\uFF41\\u1E9A\\u00E0\\u00E1\\u00E2\\u1EA7\\u1EA5\\u1EAB\\u1EA9\\u00E3\\u0101\\u0103\\u1EB1\\u1EAF\\u1EB5\\u1EB3\\u0227\\u01E1\\u00E4\\u01DF\\u1EA3\\u00E5\\u01FB\\u01CE\\u0201\\u0203\\u1EA1\\u1EAD\\u1EB7\\u1E01\\u0105\\u2C65\\u0250]","aa":"[\\uA733]","ae":"[\\u00E6\\u01FD\\u01E3]","ao":"[\\uA735]","au":"[\\uA737]","av":"[\\uA739\\uA73B]","ay":"[\\uA73D]","b":"[\\u0062\\u24D1\\uFF42\\u1E03\\u1E05\\u1E07\\u0180\\u0183\\u0253]","c":"[\\u0063\\u24D2\\uFF43\\u0107\\u0109\\u010B\\u010D\\u00E7\\u1E09\\u0188\\u023C\\uA73F\\u2184]","d":"[\\u0064\\u24D3\\uFF44\\u1E0B\\u010F\\u1E0D\\u1E11\\u1E13\\u1E0F\\u0111\\u018C\\u0256\\u0257\\uA77A]","dz":"[\\u01F3\\u01C6]","e":"[\\u0065\\u24D4\\uFF45\\u00E8\\u00E9\\u00EA\\u1EC1\\u1EBF\\u1EC5\\u1EC3\\u1EBD\\u0113\\u1E15\\u1E17\\u0115\\u0117\\u00EB\\u1EBB\\u011B\\u0205\\u0207\\u1EB9\\u1EC7\\u0229\\u1E1D\\u0119\\u1E19\\u1E1B\\u0247\\u025B\\u01DD]","f":"[\\u0066\\u24D5\\uFF46\\u1E1F\\u0192\\uA77C]","g":"[\\u0067\\u24D6\\uFF47\\u01F5\\u011D\\u1E21\\u011F\\u0121\\u01E7\\u0123\\u01E5\\u0260\\uA7A1\\u1D79\\uA77F]","h":"[\\u0068\\u24D7\\uFF48\\u0125\\u1E23\\u1E27\\u021F\\u1E25\\u1E29\\u1E2B\\u1E96\\u0127\\u2C68\\u2C76\\u0265]","hv":"[\\u0195]","i":"[\\u0069\\u24D8\\uFF49\\u00EC\\u00ED\\u00EE\\u0129\\u012B\\u012D\\u00EF\\u1E2F\\u1EC9\\u01D0\\u0209\\u020B\\u1ECB\\u012F\\u1E2D\\u0268\\u0131]","j":"[\\u006A\\u24D9\\uFF4A\\u0135\\u01F0\\u0249]","k":"[\\u006B\\u24DA\\uFF4B\\u1E31\\u01E9\\u1E33\\u0137\\u1E35\\u0199\\u2C6A\\uA741\\uA743\\uA745\\uA7A3]","l":"[\\u006C\\u24DB\\uFF4C\\u0140\\u013A\\u013E\\u1E37\\u1E39\\u013C\\u1E3D\\u1E3B\\u017F\\u0142\\u019A\\u026B\\u2C61\\uA749\\uA781\\uA747]","lj":"[\\u01C9]","m":"[\\u006D\\u24DC\\uFF4D\\u1E3F\\u1E41\\u1E43\\u0271\\u026F]","n":"[\\u006E\\u24DD\\uFF4E\\u01F9\\u0144\\u00F1\\u1E45\\u0148\\u1E47\\u0146\\u1E4B\\u1E49\\u019E\\u0272\\u0149\\uA791\\uA7A5]","nj":"[\\u01CC]","o":"[\\u006F\\u24DE\\uFF4F\\u00F2\\u00F3\\u00F4\\u1ED3\\u1ED1\\u1ED7\\u1ED5\\u00F5\\u1E4D\\u022D\\u1E4F\\u014D\\u1E51\\u1E53\\u014F\\u022F\\u0231\\u00F6\\u022B\\u1ECF\\u0151\\u01D2\\u020D\\u020F\\u01A1\\u1EDD\\u1EDB\\u1EE1\\u1EDF\\u1EE3\\u1ECD\\u1ED9\\u01EB\\u01ED\\u00F8\\u01FF\\u0254\\uA74B\\uA74D\\u0275]","oi":"[\\u01A3]","ou":"[\\u0223]","oo":"[\\uA74F]","p":"[\\u0070\\u24DF\\uFF50\\u1E55\\u1E57\\u01A5\\u1D7D\\uA751\\uA753\\uA755]","q":"[\\u0071\\u24E0\\uFF51\\u024B\\uA757\\uA759]","r":"[\\u0072\\u24E1\\uFF52\\u0155\\u1E59\\u0159\\u0211\\u0213\\u1E5B\\u1E5D\\u0157\\u1E5F\\u024D\\u027D\\uA75B\\uA7A7\\uA783]","s":"[\\u0073\\u24E2\\uFF53\\u015B\\u1E65\\u015D\\u1E61\\u0161\\u1E67\\u1E63\\u1E69\\u0219\\u015F\\u023F\\uA7A9\\uA785\\u1E9B]","ss":"[\\u00DF]","t":"[\\u0074\\u24E3\\uFF54\\u1E6B\\u1E97\\u0165\\u1E6D\\u021B\\u0163\\u1E71\\u1E6F\\u0167\\u01AD\\u0288\\u2C66\\uA787]","tz":"[\\uA729]","u":"[\\u0075\\u24E4\\uFF55\\u00F9\\u00FA\\u00FB\\u0169\\u1E79\\u016B\\u1E7B\\u016D\\u00FC\\u01DC\\u01D8\\u01D6\\u01DA\\u1EE7\\u016F\\u0171\\u01D4\\u0215\\u0217\\u01B0\\u1EEB\\u1EE9\\u1EEF\\u1EED\\u1EF1\\u1EE5\\u1E73\\u0173\\u1E77\\u1E75\\u0289]","v":"[\\u0076\\u24E5\\uFF56\\u1E7D\\u1E7F\\u028B\\uA75F\\u028C]","vy":"[\\uA761]","w":"[\\u0077\\u24E6\\uFF57\\u1E81\\u1E83\\u0175\\u1E87\\u1E85\\u1E98\\u1E89\\u2C73]","x":"[\\u0078\\u24E7\\uFF58\\u1E8B\\u1E8D]","y":"[\\u0079\\u24E8\\uFF59\\u1EF3\\u00FD\\u0177\\u1EF9\\u0233\\u1E8F\\u00FF\\u1EF7\\u1E99\\u1EF5\\u01B4\\u024F\\u1EFF]","z":"[\\u007A\\u24E9\\uFF5A\\u017A\\u1E91\\u017C\\u017E\\u1E93\\u1E95\\u01B6\\u0225\\u0240\\u2C6C\\uA763]"},"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasRedirection":false,"hasBreadcrumb":false},"homeUrl":"https:\/\/aivfisabio.com\/eng","objectID":1635,"objectType":"post","locale":"en","localeFull":"en_GB","overlayImages":{"play":{"name":"Play icon","url":"https:\/\/aivfisabio.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","path":"\/home\/hosting169443eu\/public_html\/aivfisabio.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","position":"middle_center"},"gif":{"name":"GIF icon","url":"https:\/\/aivfisabio.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","path":"\/home\/hosting169443eu\/public_html\/aivfisabio.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","position":"middle_center"}},"defautOgImage":"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/09\/Vacunas_ensayos_W.jpg","customPermalinks":true,"isUserRegistered":false,"autoSuggestKeywords":false,"connectSiteUrl":"https:\/\/rankmath.com\/auth?site=https%3A%2F%2Faivfisabio.com%2Feng&r=https%3A%2F%2Faivfisabio.com%2Feng%2Fwp-json%2Fwp%2Fv2%2Fpages%2F1635%3Fnonce%3Dd681a0eef0","maxTags":5,"trendsIcon":"<svg viewBox=\"0 0 610 610\"><path d=\"M18.85,446,174.32,290.48l58.08,58.08L76.93,504a14.54,14.54,0,0,1-20.55,0L18.83,466.48a14.54,14.54,0,0,1,0-20.55Z\" style=\"fill:#4285f4\"\/><path d=\"M242.65,242.66,377.59,377.6l-47.75,47.75a14.54,14.54,0,0,1-20.55,0L174.37,290.43l47.75-47.75A14.52,14.52,0,0,1,242.65,242.66Z\" style=\"fill:#ea4335\"\/><polygon points=\"319.53 319.53 479.26 159.8 537.34 217.88 377.61 377.62 319.53 319.53\" style=\"fill:#fabb05\"\/><path d=\"M594.26,262.73V118.61h0a16.94,16.94,0,0,0-16.94-16.94H433.2a16.94,16.94,0,0,0-12,28.92L565.34,274.71h0a16.94,16.94,0,0,0,28.92-12Z\" style=\"fill:#34a853\"\/><rect width=\"610\" height=\"610\" style=\"fill:none\"\/><\/svg>","showScore":true,"siteFavIcon":"https:\/\/aivfisabio.com\/wp-content\/uploads\/2020\/07\/Favi_Fisabio.png","canUser":{"general":false,"advanced":false,"snippet":false,"social":false,"analysis":false,"analytics":false,"content_ai":false},"isPro":false,"is_front_page":false,"trendsUpgradeLink":"https:\/\/rankmath.com\/pricing\/?utm_source=Plugin&utm_medium=CE%20General%20Tab%20Trends&utm_campaign=WP","trendsUpgradeLabel":"Upgrade","trendsPreviewImage":"https:\/\/aivfisabio.com\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/trends-preview.jpg","currentEditor":false,"homepageData":{"assessor":{"powerWords":["a cut above","absolute","absolutely","absolutely lowest","absurd","abuse","accurate","accuse","achieve","actionable","adaptable","adequate","admit","adorable","advantage","advice","affordable","aggravate","aggressive","agitated","agonizing","agony","alarmed","alarming","alienated","aligned","alive","all-inclusive","alluring","always","amazing","amp","animated","annihilate","announcing","anonymous","antagonistic","anxious","apocalypse","appalled","approved","approving","argumentative","armageddon","arrogant","ass kicking","assault","assured","astonishing","astounded","astounding","at ease","atrocious","attack","attractive","audacity","authentic","authoritative","authority","avoid","aware","awe-inspiring","awesome","awkward","backbone","backdoor","backed","backlash","backstabbing","badass","balanced","banned","bargain","barrage","basic","battle","beaming","beat down","beating","beautiful","beauty","begging","behind the scenes","belief","belong","best","best-selling","better","beware","big","billion","black market","blacklisted","blast","blessed","blinded","blissful","blood","bloodbath","bloodcurdling","bloody","blunder","blushing","bold","bomb","bona","bona fide","bonanza","bonus","bootleg","bottom line","bountiful","brave","bravery","brazen","break","breaking","breakthrough","breathtaking","bright","brilliant","broke","brutal","budget","buffoon","bullshit","bully","bumbling","buy","cadaver","calm","cancel anytime","capable","captivate","captivating","carefree","case study","cash","cataclysmic","catapult","catastrophe","caution","censored","centered","certain","certainly","certified","challenge","charming","cheap","cheat","cheat-sheet","cheer","cheerful","child-like","clarity","classified","clear","clueless","collapse","colorful","colossal","comfortable","compare","competitive","complete","completely","completeness","comprehensive","compromise","compulsive","concealed","conclusive","condemning","condescending","confess","confession","confessions","confident","confidential","conquer","conscientious","constructive","content","contrary","controlling","controversial","convenient","convert","cool","cooperative","copy","corpse","corrupt","corrupting","courage","courageous","cover-up","covert","coward","cowardly","crammed","crave","crazy","create","creative","cringeworthy","cripple","crisis","critical","crooked","crush","crushing","damaging","danger","dangerous","daring","dazzling","dead","deadline","deadly","death","decadent","deceived","deceptive","deep","defiance","definitely","definitive","defying","dejected","delicious","delight","delighted","delightful","delirious","delivered","demoralizing","deplorable","depraved","desire","desperate","despicable","destiny","destroy","detailed","devastating","devoted","diagnosed","direct","dirty","disadvantages","disastrous","discount","discover","disdainful","disempowered","disgusted","disgusting","dishonest","disillusioned","disoriented","distracted","distraught","distressed","distrustful","divulge","document","dollar","dominate","doomed","double","doubtful","download","dreadful","dreamy","drive","drowning","dumb","dynamic","eager","earnest","easily","easy","economical","ecstatic","edge","effective","efficient","effortless","elated","eliminate","elite","embarrass","embarrassed","embarrassing","emergency","emerging","emphasize","empowered","enchant","encouraged","endorsed","energetic","energy","enormous","enraged","enthusiastic","envy","epic","epidemic","essential","ethical","euphoric","evil","exactly","exasperated","excellent","excited","excitement","exciting","exclusive","exclusivity","excruciating","exhilarated","expensive","expert","explode","exploit","explosive","exposed","exquisite","extra","extraordinary","extremely","exuberant","eye-opening","fail","fail-proof","failure","faith","famous","fantasy","fascinating","fatigued","faux","faux pas","fearless","feast","feeble","festive","fide","fierce","fight","final","fine","fired","first","first ever","flirt","fluid","focus","focused","fool","fooled","foolish","forbidden","force-fed","forever","forgiving","forgotten","formula","fortune","foul","frantic","free","freebie","freedom","frenzied","frenzy","frightening","frisky","frugal","frustrated","fulfill","fulfilled","full","fully","fun","fun-loving","fundamentals","funniest","funny","furious","gambling","gargantuan","genius","genuine","gift","gigantic","giveaway","glamorous","gleeful","glorious","glowing","goddamn","gorgeous","graceful","grateful","gratified","gravity","great","greatest","greatness","greed","greedy","gripping","grit","grounded","growth","guaranteed","guilt","guilt-free","gullible","guts","hack","happiness","happy","harmful","harsh","hate","have you heard","havoc","hazardous","healthy","heart","heartbreaking","heartwarming","heavenly","hell","helpful","helplessness","hero","hesitant","hidden","high tech","highest","highly effective","hilarious","hoak","hoax","honest","honored","hope","hopeful","horribly","horrific","horrifying","horror","hostile","how to","huge","humility","humor","hurricane","hurry","hypnotic","idiot","ignite","illegal","illusive","imagination","immediately","imminently","impatience","impatient","impenetrable","important","impressive","improved","in the zone","incapable","incapacitated","incompetent","inconsiderate","increase","incredible","indecisive","indulgence","indulgent","inexpensive","inferior","informative","infuriated","ingredients","innocent","innovative","insane","insecure","insider","insidious","inspired","inspiring","instant savings","instantly","instructive","insult","intel","intelligent","intense","interesting","intriguing","introducing","invasion","investment","iron-clad","ironclad","irresistible","irs","is here","jackpot","jail","jaw-dropping","jealous","jeopardy","jittery","jovial","joyous","jubilant","judgmental","jumpstart","just arrived","keen","kickass","kickstart","kill","killed","killing","kills","know it all","lame","largest","lascivious","last","last chance","last minute","latest","laugh","laughing","launch","launching","lavishly","lawsuit","lazy","left behind","legendary","legitimate","liberal","liberated","lick","lies","life-changing","lifetime","light","lighthearted","likely","limited","literally","little-known","loathsome","lonely","looming","loser","lost","love","lucrative","lunatic","lurking","lust","luxurious","luxury","lying","magic","magical","magnificent","mainstream","malicious","mammoth","manipulative","marked down","massive","master","masterclass","maul","mediocre","meditative","meltdown","memorability","memorable","menacing","mesmerizing","meticulous","mind-blowing","minimalist","miracle","mired","mischievous","misgiving","missing out","mistake","monetize","money","moneyback","moneygrubbing","monumental","most important","motivated","mouth-watering","murder","mystery","nail","naked","natural","naughty","nazi","nest egg","never","new","nightmare","no good","no obligation","no one talks about","no questions asked","no risk","no strings attached","non-controlling","noted","novelty","now","obnoxious","obsessed","obsession","obvious","odd","off-kilter","off-limits","off-the record","offensive","official","okay","on-demand","open-minded","opportunities","optimistic","ordeal","outlawed","outrageousness","outstanding","overcome","overjoyed","overnight","overwhelmed","packed","painful","painless","painstaking","pale","panic","panicked","paralyzed","pas","passionate","pathetic","pay zero","payback","perfect","peril","perplexed","perspective","pessimistic","pioneering","piranha","pitfall","pitiful","placid","plague","played","playful","pleased","pluck","plummet","plunge","poison","poisonous","polarizing","poor","popular","portfolio","pound","powerful","powerless","practical","preposterous","prestige","price","priceless","pride","prison","privacy","private","privileged","prize","problem","productive","professional","profit","profitable","profound","promiscuous","promising","promote","protect","protected","proven","provocative","provoke","psychological","pummel","punch","punish","pus","quadruple","quality","quarrelsome","quick","quick-start","quickly","quiet","radiant","rare","ravenous","rebellious","recession-proof","reckoning","recognized","recommend","recreate","reduced","reflective","refugee","refund","refundable","reject","relaxed","release","relentless","reliable","remarkable","replicate","report","reprimanding","repulsed","repulsive","research","resentful","resourceful","responsible","responsive","rested","restricted","results","retaliating","reveal","revealing","revenge","revengeful","revisited","revolting","revolutionary","reward","rich","ridiculous","risky","riveting","rookie","rowdy","ruin","rules","ruthless","sabotaging","sacred","sadistic","sadly","sadness","safe","safety","sale","sampler","sarcastic","satisfied","savage","savagery","save","savings","savvy","scam","scandal","scandalous","scarce","scared","scary","scornful","scream","searing","secret","secret agenda","secret plot","secrets","secure","security","seductive","seething","seize","selected","self-hating","self-sufficient","sensational","senseless","sensual","serene","seriously","severe","sex","sexy","shaking","shameful","shameless","shaming","shatter","shellacking","shocking","should","shrewd","sick and tired","signs","silly","simple","simplicity","simplified","simplistic","sincere","sinful","sins","six-figure","sizable","sizzle","sizzled","sizzles","sizzling","sizzlingly","skill","skyrocket","slaughter","slave","sleazy","sleeping","sly","smash","smiling","smug","smuggle","smuggled","sneak-peek","sneaky","sniveling","snob","snooty","snotty","soar","soaring","solid","solution","spank","special","spectacular","speedy","spell-binding","spine","spirit","spirited","spiteful","spoiler","spontaneous","spotlight","spunky","squirming","stable","staggering","startling","steady","steal","stealthy","steamy","step-by-step","still","stoic","stop","strange","strangle","strategy","stressed","strong","strongly suggest","struggle","stuck up","studies","stunning","stupid","stupid-simple","sturdy","sublime","succeed","success","successful","suck","suddenly","suffer","sunny","super","super-human","superb","supercharge","superior","supported","supportive","sure","sure fire","surefire","surge","surging","surprise","surprised","surprising","survival","survive","suspicious","sweaty","swoon","swoon-worthy","tailspin","tank","tantalizing","targeted","tawdry","tease","technology","teetering","tempting","tenacious","tense","terrible","terrific","terrified","terrifying","terror","terrorist","tested","thankful","the truth","threaten","threatened","thrilled","thrilling","thug","ticked off","tickled","timely","today","torture","toxic","track record","trade secret","tragedy","tragic","transform","transparency","trap","trapped","trauma","traumatized","treacherous","treasure","tremendous","trend","tricks","triggers","triple","triumph","truly","trusting","trustworthy","truth","truthful","turbo-charge","turbocharges","tweaks","twitching","ultimate","unadulterated","unassuming","unauthorized","unbelievable","unburdened","uncaring","uncensored","uncertain","uncomfortable","unconditional","uncontrollable","unconventional","uncovered","undeniable","under priced","undercover","underground","underhanded","underused","unexpected","unforgettable","unheard of","unhurried","uninterested","unique","unjustified","unknowingly","unleashed","unlimited","unlock","unparalleled","unpopular","unreliable","unresponsive","unseen","unstable","unstoppable","unsure","unsurpassed","untapped","unusual","up-sell","upbeat","uplifted","uplifting","urge","urgent","useful","useless","validate","valor","valuable","value","vanquish","vaporize","venomous","verify","vibrant","vicious","victim","victory","vigorous","vilified","vindictive","violated","violent","volatile","vulnerable","waiting","wanted","wanton","warning","waste","weak","wealth","weird","what no one tells you","whip","whopping","wicked","wild","willpower","withheld","wonderful","wondrous","woozy","world","worry","worst","worthwhile","wounded","wreaking","youthful","zen","zinger"],"diacritics":true,"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasBreadcrumb":false,"serpData":{"title":"%sitename% %page% %sep% %sitedesc%","description":"","titleTemplate":"%sitename% %page% %sep% %sitedesc%","descriptionTemplate":"","focusKeywords":"","breadcrumbTitle":"Home","robots":{"index":true},"advancedRobots":{"max-snippet":"-1","max-video-preview":"-1","max-image-preview":"large"},"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":""}}},"tocTitle":"Table of Contents","tocExcludeHeadings":[],"listStyle":"ul"},"_links":{"self":[{"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/pages\/1635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/comments?post=1635"}],"version-history":[{"count":30,"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/pages\/1635\/revisions"}],"predecessor-version":[{"id":7417,"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/pages\/1635\/revisions\/7417"}],"wp:attachment":[{"href":"https:\/\/aivfisabio.com\/eng\/wp-json\/wp\/v2\/media?parent=1635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}